What are the opening hours?

Monday 8:30am - 5pm Tuesday 8:30am - 5pm Wednesday 8:30am - 5pm Thursday 8:30am - 5pm Friday 8:30am - 5pm

Cellvizio by Mauna Kea Technologies

Home
United States
Boston, MA
Cellvizio by Mauna Kea Technologies

Cellvizio is the real-time in vivo cellular imaging platform that revolutionizes the way physicians

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative change in medicine.

02/02/2026

An educational day at the CellTolerance Workshop in Bamberg! It was a privilege to engage with such dedicated participants and witness the impact of the CellTolerance test through three insightful live cases demonstrating how cells react to specific food triggers. Seeing this clinical application in real time underscores the importance of innovation in modern medicine.

A huge thank you to Prof. Dr. med. Jost Langhorst and the entire team at Sozialstiftung Bamberg for their incredible hospitality and clinical expertise. Collaborative days like these drive the future of integrated care! For a deeper look at how Prof. Dr. med. Langhorst uses CellTolerance to detect underlying food intolerances and provide lasting relief, visit: https://hubs.la/Q041mqsp0

01/27/2026

Traditional testing often relies on delayed markers. The test provides immediate diagnostic clarity by revealing cellular-level gut reactions to food in real-time. No more guesswork. Identify functional mucosal barrier impairment with cellular precision to give patients answers and relief, faster.

Learn more: https://hubs.la/Q040vrbP0

01/22/2026

The free app is easy to use, from anywhere. Enhance your image pattern recognition skills and use samples from our video library as references to compare your cases with examples from a wide range of indications.

01/15/2026

Today we announce a breakthrough fourth quarter, driven by significant U.S. expansion and the growth of .

Key performance highlights include a 19% surge in Q4 revenue, fueled by powerful momentum in pancreatic cyst indication and CellTolerance’s milestone €1M in global FY2025 sales. We further solidified U.S. market leadership by securing four new system sales in Q4 and initiating a strategic partnership with TaeWoong Medical USA. Driven by this record-breaking performance in the U.S. and enhanced operational visibility, we enter 2026 focused and ready for the year ahead.

Read the full PR: https://hubs.la/Q03_0XXW0

01/12/2026

Huge milestone for the Cellvizio by Mauna Kea Technologies team as we support Dr. Bharat Panuganti in the first laryngeal cases at Barnes-Jewish Hospital. Conventional imaging shows the "what," but shows the "why" at a cellular level. Better margins, better decisions, better outcomes. Seeing this level of precision in the hands of such a skilled team is inspiring!

01/07/2026

Physicians, there is no time like the new year to reconsider what technologies will best support your patient management in the months to come.

Make the most of your new year’s resolution and consider how Cellvizio real-time, in vivo cellular imaging could revolutionize your practice: https://hubs.ly/Q03ZSzB10

01/01/2026

What a remarkable year 2025 has been, made possible by your support. In 2026, we're committed to setting new standards in care with precision and purpose. Thank you for being part of our journey. Together, we can .
Happy New Year!

12/30/2025

We are wrapping up a milestone year for Mauna Kea Technologies, and as we close out the year we wish you and your loved ones safe and healthy holidays.

12/29/2025

Conventional imaging and fluid analysis for often leave physicians in the dark, leading to misdiagnosis or unnecessary, high-risk surgeries. As highlighted in this study, needle-based Confocal Laser Endomicroscopy ( ) using AI enables more precise clinical decision-making, ensuring that surgical interventions are reserved for those who truly need them.

Read the full publication: https://hubs.la/Q03Z7t0J0

12/23/2025

We want to take a moment to express our immense gratitude to everyone who made 2025 a transformational year here at MKT! Together, we are on a mission to revolutionize the world of healthcare by advancing how physicians diagnose and treat patients using the incredible technology of Cellvizio advanced imaging.

12/18/2025

We are thrilled to announce is expanding to University Hospital of Vienna!

This groundbreaking program, led by Prof. Johann Hammer, marks a significant step forward in patient care and research. Prof. Hammer and his team will be utilizing the CellTolerance test for patients suffering from food-related .

12/17/2025

We are honored to partner with Henry Ford Health as they integrate nCLE into their standard clinical workflow.

By bringing cellular visualization directly into the endoscopy suite, the Henry Ford team is moving beyond traditional imaging. This enables real-time, cellular-level insights inside pancreatic cysts, empowering clinicians to make more confident diagnoses and tailor treatment plans faster than ever before.

Address

24 Denby Road, Suite 140
Boston, MA
02134

Opening Hours

Monday	8:30am - 5pm
Tuesday	8:30am - 5pm
Wednesday	8:30am - 5pm
Thursday	8:30am - 5pm
Friday	8:30am - 5pm

Website

http://www.maunakeatech.com/

Alerts

Be the first to know and let us send you an email when Cellvizio by Mauna Kea Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Boston?

Our Story

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.